comparemela.com

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®) met its primary endpoint of progression-free survival (PFS). Patients in the trial had u...

Related Keywords

Canada ,California ,United States ,Switzerland ,Washington ,American ,Roger Dansey ,David Caouette ,Exchange Commission ,Cancer Statistics Center ,Nasdaq ,Genentech ,Seagen Inc ,Roche Group ,Breast Cancer Development Program ,Lab Abnormalities ,Twitter ,Linkedin ,American Cancer Society ,Chief Medical Officer ,Response Evaluation Criteria ,Solid Tumors ,Cancer Development ,Fetal Toxicity ,Hepatic Impairment ,Prescribing Information ,Quarterly Report ,Cancer Statistics ,Accessed July ,Breast Cancer ,Positive Breast Cancer ,Novel Treatment ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.